A recent analysis of trends in payer decisions related to reimbursement indicates that payers are looking at a range of issues, including disease prevalence, with new levels of scrutiny and are working to rein in pricing of many rare disease treatments.
Because of the unknowns around revenue streams, biotech valuation may appear to be more guesswork than science. However, common valuation methods can help account for some of the product-line uncertainty.
Tim Ring, former chairman and CEO of C.R. Bard, shares how he and his spouse retired to build TEAMFund, a $30 million impact investment fund focused on having a positive impact on health in some of the most resource constrained areas of the world.
Life sciences companies seeking to raise capital or form early partnerships with strategic players often make avoidable mistakes. Here are some tips that can increase your probability of a successful transaction.
Repeat entrepreneur is a term you might hear often in the context of life sciences company creation and investment, so we wanted to take a moment to unpack it and offer lessons for those on either side of the table.
Sam Cobb, managing director and CEO of Australian biotech AdAlta, talks about how the company has struggled to procure funding over the years and the strategies they employed to finally get listed on the Australian Securities Exchange.